Ascites — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for ascites. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
8
Active US patents
50/100
Avg vulnerability
—
Annual revenue covered

Originators in Ascites

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Searle/Pfizer) 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating ascites. Each bar = one year. Y-axis scaled to peak year (8 patents).

8
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aldactone
spironolactone
 Generic (originally Searle/Pfizer) 8 50 — 2036-10-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11395828 Aldactone method of use 70 2036-10-28
9757394 Aldactone method of use 62 2036-10-28
11491166 Aldactone formulation 50 2036-10-28
11389461 Aldactone formulation 50 2036-10-28
10624906 Aldactone formulation 42 2036-10-28
10888570 Aldactone formulation 42 2036-10-28
10493083 Aldactone formulation 42 2036-10-28
10660907 Aldactone formulation 42 2036-10-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10660907 Aldactone formulation 42 2036-10-28
10888570 Aldactone formulation 42 2036-10-28
10493083 Aldactone formulation 42 2036-10-28
10624906 Aldactone formulation 42 2036-10-28
11491166 Aldactone formulation 50 2036-10-28
11389461 Aldactone formulation 50 2036-10-28
9757394 Aldactone method of use 62 2036-10-28
11395828 Aldactone method of use 70 2036-10-28

Related